1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

A. Ribas, Jason Chesney, Georgina V. Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Höeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Scott J. Diede, J R Anderson, Sheryl Treichel, Emily Chan, F. Stephen Hodi, Helen Gogas